Records containing: Recurrent Grade 3 Follicular Lymphoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2019-06-14A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma
-
CLINICAL_TRIALS study record update · 2019-05-29Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2019-04-17Clinical Study of CD19/CD22 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas
-
CLINICAL_TRIALS study record update · 2019-02-26Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)
-
CLINICAL_TRIALS study record update · 2019-01-04Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2019-01-04Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies
-
CLINICAL_TRIALS study record update · 2018-10-09A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma
-
CLINICAL_TRIALS study record update · 2018-07-02Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
-
CLINICAL_TRIALS study record update · 2018-06-12A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
-
CLINICAL_TRIALS study record update · 2018-06-06A Phase II Study of MLN8237 Alone and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
-
CLINICAL_TRIALS study record update · 2018-06-04Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma
-
CLINICAL_TRIALS study record update · 2018-05-18A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma
-
CLINICAL_TRIALS study record update · 2018-05-17A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
-
CLINICAL_TRIALS study record update · 2018-04-26Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma
-
CLINICAL_TRIALS study record update · 2018-04-11Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies
-
CLINICAL_TRIALS study record update · 2018-03-06A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma
-
CLINICAL_TRIALS study record update · 2017-11-09A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
-
CLINICAL_TRIALS study record update · 2017-10-09Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma
-
CLINICAL_TRIALS study record update · 2017-09-25A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies
-
CLINICAL_TRIALS study record update · 2017-07-02A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
-
CLINICAL_TRIALS study record update · 2017-06-29A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies
-
CLINICAL_TRIALS study record update · 2017-05-30Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial
-
CLINICAL_TRIALS study record update · 2017-05-25A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma
-
CLINICAL_TRIALS study record update · 2017-05-24A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)
-
CLINICAL_TRIALS study record update · 2017-05-24A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma